{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443346749
| IUPAC_name = (''RS'')-4-(Ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate
| image = Mebeverine.svg
| width = 300
| image2 = Mebeverine2.png
| chirality = [[Racemic mixture]]

<!--Clinical data-->
| tradename = Colofac, Duspamen, Duspatalin and others
| Drugs.com = {{drugs.com|international|mebeverine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = P
| legal_US = Not approved
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2753-45-9
| ATC_prefix = A03
| ATC_suffix = AA04
| PubChem = 4031
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3891
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7F80CC3NNV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04868
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 282121

<!--Chemical data-->
| C=25 | H=35 | N=1 | O=5 
| molecular_weight = 429.6 g/mol
| smiles = O=C(OCCCCN(C(C)Cc1ccc(OC)cc1)CC)c2cc(OC)c(OC)cc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VYVKHNNGDFVQGA-UHFFFAOYSA-N
}}

'''Mebeverine''' is a [[Pharmaceutical drug|drug]] used to alleviate some of the symptoms of [[irritable bowel syndrome]]. It works by relaxing the muscles in and around the gut.<ref name=NZlabel2017>{{cite web|title=Colofac data sheet|url=http://www.medsafe.govt.nz/profs/datasheet/c/colofactab.pdf|publisher=New Zealand Medicines and Medical Devices Safety Authority|accessdate=21 July 2017|date=14 June 2017}}</ref>

[[File:Mebeverine(Colofac) 135mg UK.jpg|thumb|Mebeverine (Colofac) 135&nbsp;mg, U.K.]]

==Medical use==
Mebeverine is used to alleviate some of the symptoms of [[irritable bowel syndrome]] (IBS) and related conditions these conditions; specifically stomach pain and cramps, persistent diarrhea, and flatulence.<ref name=UKlabel2016>{{cite web|title=Colofac Tablets 135mg - Summary of Product Characteristics (SPC)|url=https://www.medicines.org.uk/emc/medicine/2067|publisher=UK Electronic Medicines Compendium|accessdate=21 July 2017|language=en|date=26 August 2016}}</ref>

Data from controlled clinical trials have not found a difference from placebo in the alleviating stomach pain in people with IBS.<ref>{{cite journal|last1=Annaházi|first1=A|last2=Róka|first2=R|last3=Rosztóczy|first3=A|last4=Wittmann|first4=T|title=Role of antispasmodics in the treatment of irritable bowel syndrome.|journal=World journal of gastroenterology|date=28 May 2014|volume=20|issue=20|pages=6031-43|doi=10.3748/wjg.v20.i20.6031|pmid=24876726|pmc=4033443}}</ref><ref>{{cite journal|last1=Darvish-Damavandi|first1=M|last2=Nikfar|first2=S|last3=Abdollahi|first3=M|title=A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.|journal=World journal of gastroenterology|date=7 February 2010|volume=16|issue=5|pages=547-53|pmid=20128021|pmc=2816265}}</ref>

It has not been tested in pregnant women nor in pregnant animals so pregnant women should not take it; it is expressed at low levels in breast milk, while no adverse effects have been reported in infants, breastfeeding women should not take this drug.<ref name=NZlabel2017/>

==Adverse effects==
Adverse effects include hypersensitivity reactions and allergic reactions, immune system disorders, skin disorders including hives, edema and widespread rashes.<ref name=UKlabel2016/>

Additionally, the following adverse effects have been reported: heartburn, indigestion, constipation, loss of appetite, general malaise, dizziness, insomnia, headache, and decreased pulse rate.<ref name=NZlabel2017/>

It does not have systemic [[anticholinergic]] side effects.<ref name=UKlabel2016/>

==Mechanism of action==
Mebeverine is an [[anticholinergic]] but its mechanism of action is not known; it appears to work directly on smooth muscle within the gastrointestinal tract and may have an anesthetic effect, may affect [[calcium channel]]s, and may affect muscarinic receptors.<ref name=UKlabel2016/>

It is metabolized mostly by [[esterase]]s, and almost completely.  The metabolites are excreted in urine.<ref name=UKlabel2016/>

==History==
It is a second generation [[papaverine]] analog, and was first synthesized around the same time as [[verapamil]].<ref>{{cite book|last1=Sneader|first1=Walter|title=Drug Discovery: A History|date=2005|publisher=John Wiley & Sons|isbn=9780471899792|page=132|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA132|language=en}}</ref>

It was first registered in 1965.<ref>[http://druginfosys.com/Drug.aspx?DrugCode=438&DrugName=Mebeverine&type=1 Mebeverine page at druginfosys] Page accessed Feb 1, 2015</ref>

==Availability==
Mebeverine is a [[generic drug]] and is available internationally under many brand names.<ref>[http://www.drugs.com/international/mebeverine.html International page at drugs.com for Mebeverine] Page accessed Feb 1, 2015</ref>

==References==
{{Reflist|2}}


{{Drugs for functional gastrointestinal disorders}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Amines]]
[[Category:Benzoates]]
[[Category:Motility stimulants]]
[[Category:Muscarinic antagonists]]
[[Category:Phenol ethers]]